Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2927 of 5804
-
Smart belt aims to stop fainting spells in nerve disorder patients
Symptom relief CompletedThe automated inflatable abdominal binder is an investigational device for the treatment of orthostatic hypotension (low blood pressure on standing) in patients with autonomic failure. The purpose of this study is to determine safety and effectiveness of the automated abdominal b…
Phase: PHASE1, PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Educational therapy boosts motor skills in kids with cerebral palsy
Symptom relief CompletedCerebral palsy is the most frequent cause of physical disability in childhood. The Petö Method proposes a comprehensive pedagogical-therapeutic approach to improve functionality. Historically, the Petö Method (Conductive Education) has faced skepticism regarding its clinical effi…
Sponsor: Universidad de Almeria • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Targeted drug afatinib tested on Hard-to-Treat cancers
Disease control OngoingThis phase II MATCH treatment trial tests how well afatinib works in treating patients with cancer that has certain genetic changes. Afatinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the EGFR gen…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill aims to stop chemo sickness in breast cancer patients
Symptom relief OngoingNausea and vomiting (feeling sick to your stomach and throwing up) are two of the most common unpleasant side effects of chemotherapy agents (drugs specifically used to treat cancer) that will be used for cancer treatment. If nausea and vomiting are not controlled, they could lea…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New test guides myeloma treatment choices
Knowledge-focused OngoingThis will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
Phase: NA • Sponsor: SkylineDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Could a common cholesterol drug protect bones and hearts after spinal injury?
Disease control TerminatedRationale: After having a spinal cord injury (SCI), people develop changes in their body composition that influences their long-term health. Individuals with paralysis after SCI will have large declines in their bone density ant increases in fat mass which increases their risk of…
Phase: PHASE2 • Sponsor: Dr. B. Catharine. Craven • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Exercise and online therapy show promise for cancer fatigue
Symptom relief CompletedThis randomized pilot phase II trial studies how well exercise intervention with or without internet-based cognitive behavior therapy works in reducing fatigue in participants with prostate cancer that has spread to other places in the body and usually cannot be cured or controll…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Can talking about trauma ease PTSD after spinal cord injury?
Symptom relief CompletedThe study evaluates the effectiveness of Prolonged Exposure Therapy on a population of individuals with spinal cord injuries. Participants will be randomly assigned to either a treatment as usual or Prolonged Exposure therapy group.
Phase: NA • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
MIT tests flickering lights and tones to fight Alzheimer's
Knowledge-focused Recruiting nowDespite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that…
Phase: PHASE2 • Sponsor: Massachusetts Institute of Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Promising combo for tough breast cancers hits early hurdle
Disease control TerminatedThis phase I/II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast cancer that has spread to other places in the body…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThe purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults. Boserolimab monotherapy or boserolimab plus pembrolizumab combination therapy will be administered in…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows limited promise for rare brain lining cancer
Disease control CompletedThis research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases. The names of the study interventions involved in this study are: * Ipilimumab * Nivolumab
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedPhase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Which prostate radiation is easier on patients? new trial aims to find out
Disease control OngoingH17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Talking it out: new program aims to cut drug use and HIV in young gay couples
Disease control CompletedThis research examines the efficacy of an individually-delivered intervention tailored for YMSM in relationships. The intervention - termed PARTNER - utilizes a brief (4 session) motivational interviewing format to target Pre-Exposure Prophylaxis (PrEP) uptake/adherence, HIV tran…
Phase: NA • Sponsor: Hunter College of City University of New York • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
3D scanner could revolutionize foot alignment diagnosis
Diagnosis CompletedThe automated TALAS measurement tool, working with the Cone Beam 3D scanner under load, provides a reproducible measurement of the Foot Ankle Offset (FAO). It is possible to determine an average value and the standard deviation of FAO in the relevant population. And to differenti…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat childhood cancers
Disease control CompletedThis pilot study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination of pembrolizumab, decitabine and fixed-dose hypofractionated index site radiotherapy in pediatric and young adult patients with relapsed, refractory or progress…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Cancer drug combo shows promise but study halted early
Disease control TerminatedThis is a Phase II study of pembrolizumab plus mifepristone in advanced breast cancer patients. The study will include a safety lead in of ten patients. Patients who are deemed eligible and have signed informed consent will be treated with pembrolizumab at a fixed dose of 200 mg …
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail targets rare protein disease in early trial
Disease control CompletedThis phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Fisetin: a berry compound that could fight frailty in older women?
Symptom relief ENROLLING_BY_INVITATIONThis is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC